HCC has a unique tumor microenvironment that is immunosuppressive, allowing the tumor to avoid detection by the immune system.[13] This immunosuppressive setting is influenced by the existence of specific immune cells, referred to as tumor‐infiltrating lymphocytes, which encompass CD8‐positive cytotoxic T cells, as well as the presence of immune checkpoint molecules like programmed death‐ligand 1 (PD‐L1).[14] In order to address this issue, the utilization of two monoclonal antibody drugs, namely atezolizumab and bevacizumab, has been incorporated into the treatment of HCC. Here, CD8A is linked to hepatocellular carcinoma.